Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden.
Metrics to compare | LIPUM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLIPUMPeersSector | |
---|---|---|---|---|
P/E Ratio | −4.4x | −6.1x | −0.5x | |
PEG Ratio | −0.16 | −0.11 | 0.00 | |
Price/Book | 96.3x | 8.7x | 2.6x | |
Price / LTM Sales | - | 80.4x | 3.2x | |
Upside (Analyst Target) | 62.4% | 63.6% | 38.8% | |
Fair Value Upside | Unlock | 9.4% | 5.4% | Unlock |